May 24 2022

Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines

By |2022-05-24T05:22:45-04:00May 24th, 2022|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 24, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted cytokine from a homogeneous mixture of two different cytokines in a fluid.  Several adverse health conditions are caused by excess quantities of particular components in blood or ...

Feb 1 2022

Halberd Achieves Landmark Selective Elimination of Tau From an Antigen Mixture

By |2022-01-31T18:55:40-05:00February 1st, 2022|Featured, Investor News, Medical, News|0 Comments

Tau has been shown to be important in the development of Alzheimer’s Disease. Eradication of tau accomplished without reducing levels of non-target cytokine. Jackson Center, PA, February 1, 2022 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to selectively reduce and control the level of one element in a heterogeneous mixture containing two elements ...

Go to Top